.png&w=384&q=75)
Nesudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension.
Netarsudil is a Rho kinase inhibitor, works at the cellular level within the trabecular outflow pathway
to relax actin-myosin. This causes relaxation within the trabecular meshwork and the inner wall of
Schlemm's canal, and decreases episcleral venous pressure (EVP).
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
This eye drops is contraindicated in patients who are hypersensitive to any component of this
preparation.
Precautions:
● For ophthalmic use only.
● To avoid possible contamination of the drops, do not touch the dropper tip or to any surface.
● Netarsudil can be used with other topical eye drug products, but they should be administered at
least 5 minutes apart from each other.
● Contact lenses should be removed prior to instillation of Netarsudil and may be reinserted 15
minutes following its administration.
The most common ocular adverse reaction observed in controlled clinical studies with Netarsudil was
conjunctival hyperemia, corneal verticillata, instillation site pain, corneal staining and blurred vision.
There are no adequate and well-controlled studies of Netarsudil ophthalmic solution in
pregnant women to inform any drug associated risk. However, systemic exposure to Netarsudil from
ocular administration is low.
There are no data on the presence of Netarsudil in human milk, the effects on the
breastfed infant, or the effects on milk production.
Nesudil Ophthalmic Solution: Each ml contains Netarsudil Dimesylate INN equivalent to Netarsudil
0.20 mg.
Preservative: Sodium Perborate BP 0.01%.